Description of the medicine: Survanta (Survanta)
The active substance is the surfactant beraktant, which reduces the surface tension in the walls of the alveoli and thereby protects them from subsidence with a decrease in transpulmonary pressure.
Used, like kurosurf and exosurf, with respiratory distress syndrome in premature infants.
Intraartally administered at a dose of 4 ml / kg under conditions of mechanical ventilation.
Release form: 2,5% suspension in disposable bottles of 8 ml.
Surfactants are a relatively new group of drugs. A number of modern preparations of this group have been created (surfactant from the lungs of calves and pigs, semi-synthetic substances, etc.), which are currently in the stage of in-depth study.